Financhill
Sell
27

PCVX Quote, Financials, Valuation and Earnings

Last price:
$87.77
Seasonality move :
-4.57%
Day range:
$80.30 - $89.65
52-week range:
$58.10 - $121.06
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.26x
Volume:
2.3M
Avg. volume:
1.1M
1-year change:
47.05%
Market cap:
$11.1B
Revenue:
--
EPS (TTM):
-$4.60

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
PCVX
Vaxcyte
-- -$0.99 -- -42.58% $149.89
AIM
AIM ImmunoTech
$100K -$0.09 -23.08% -53.85% $2.75
CVM
CEL-SCI
-- -- -- -- $7.73
IGC
IGC Pharma
$204K -$0.03 -- -40% $3.63
NBY
NovaBay Pharmaceuticals
$2.5M -$0.24 -60.77% -99.16% $7.30
PFE
Pfizer
$17.3B $0.47 27.51% 12.4% $31.18
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
PCVX
Vaxcyte
$89.29 $149.89 $11.1B -- $0.00 0% --
AIM
AIM ImmunoTech
$0.19 $2.75 $12.1M -- $0.00 0% 52.11x
CVM
CEL-SCI
$0.41 $7.73 $30.4M -- $0.00 0% --
IGC
IGC Pharma
$0.33 $3.63 $25.8M -- $0.00 0% 19.48x
NBY
NovaBay Pharmaceuticals
$0.68 $7.30 $3.3M -- $0.00 0% 0.07x
PFE
Pfizer
$26.22 $31.18 $148.6B 35.43x $0.42 6.41% 2.51x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
PCVX
Vaxcyte
-- 1.598 -- --
AIM
AIM ImmunoTech
48.41% 0.799 17.25% 0.71x
CVM
CEL-SCI
-- 0.840 -- --
IGC
IGC Pharma
1.8% -1.323 0.41% 0.58x
NBY
NovaBay Pharmaceuticals
4.54% 0.365 1.51% 0.75x
PFE
Pfizer
41.92% 0.489 40.56% 0.64x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
PCVX
Vaxcyte
-- -$139.6M -- -- -- -$98.8M
AIM
AIM ImmunoTech
$27K -$4.5M -219.06% -256.33% -9994.29% -$3.3M
CVM
CEL-SCI
-- -$6.7M -- -- -- -$4.6M
IGC
IGC Pharma
$198K -$1.8M -135.4% -137.43% -427.19% -$1.1M
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M
PFE
Pfizer
$12.4B $5.3B 2.66% 4.63% 31.06% $6.1B

Vaxcyte vs. Competitors

  • Which has Higher Returns PCVX or AIM?

    AIM ImmunoTech has a net margin of -- compared to Vaxcyte's net margin of -10571.43%. Vaxcyte's return on equity of -- beat AIM ImmunoTech's return on equity of -256.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    PCVX
    Vaxcyte
    -- -$0.83 --
    AIM
    AIM ImmunoTech
    77.14% -$0.06 $5.6M
  • What do Analysts Say About PCVX or AIM?

    Vaxcyte has a consensus price target of $149.89, signalling upside risk potential of 67.87%. On the other hand AIM ImmunoTech has an analysts' consensus of $2.75 which suggests that it could grow by 1350.42%. Given that AIM ImmunoTech has higher upside potential than Vaxcyte, analysts believe AIM ImmunoTech is more attractive than Vaxcyte.

    Company Buy Ratings Hold Ratings Sell Ratings
    PCVX
    Vaxcyte
    8 0 0
    AIM
    AIM ImmunoTech
    1 0 0
  • Is PCVX or AIM More Risky?

    Vaxcyte has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AIM ImmunoTech has a beta of -0.363, suggesting its less volatile than the S&P 500 by 136.26%.

  • Which is a Better Dividend Stock PCVX or AIM?

    Vaxcyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vaxcyte pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PCVX or AIM?

    Vaxcyte quarterly revenues are --, which are smaller than AIM ImmunoTech quarterly revenues of $35K. Vaxcyte's net income of -$103.1M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, Vaxcyte's price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxcyte is -- versus 52.11x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PCVX
    Vaxcyte
    -- -- -- -$103.1M
    AIM
    AIM ImmunoTech
    52.11x -- $35K -$3.7M
  • Which has Higher Returns PCVX or CVM?

    CEL-SCI has a net margin of -- compared to Vaxcyte's net margin of --. Vaxcyte's return on equity of -- beat CEL-SCI's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    PCVX
    Vaxcyte
    -- -$0.83 --
    CVM
    CEL-SCI
    -- -$0.14 --
  • What do Analysts Say About PCVX or CVM?

    Vaxcyte has a consensus price target of $149.89, signalling upside risk potential of 67.87%. On the other hand CEL-SCI has an analysts' consensus of $7.73 which suggests that it could grow by 1787.1%. Given that CEL-SCI has higher upside potential than Vaxcyte, analysts believe CEL-SCI is more attractive than Vaxcyte.

    Company Buy Ratings Hold Ratings Sell Ratings
    PCVX
    Vaxcyte
    8 0 0
    CVM
    CEL-SCI
    1 0 0
  • Is PCVX or CVM More Risky?

    Vaxcyte has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.718%.

  • Which is a Better Dividend Stock PCVX or CVM?

    Vaxcyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vaxcyte pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PCVX or CVM?

    Vaxcyte quarterly revenues are --, which are smaller than CEL-SCI quarterly revenues of --. Vaxcyte's net income of -$103.1M is lower than CEL-SCI's net income of -$6.9M. Notably, Vaxcyte's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxcyte is -- versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PCVX
    Vaxcyte
    -- -- -- -$103.1M
    CVM
    CEL-SCI
    -- -- -- -$6.9M
  • Which has Higher Returns PCVX or IGC?

    IGC Pharma has a net margin of -- compared to Vaxcyte's net margin of -416.75%. Vaxcyte's return on equity of -- beat IGC Pharma's return on equity of -137.43%.

    Company Gross Margin Earnings Per Share Invested Capital
    PCVX
    Vaxcyte
    -- -$0.83 --
    IGC
    IGC Pharma
    48.06% -$0.02 $7.5M
  • What do Analysts Say About PCVX or IGC?

    Vaxcyte has a consensus price target of $149.89, signalling upside risk potential of 67.87%. On the other hand IGC Pharma has an analysts' consensus of $3.63 which suggests that it could grow by 1026.13%. Given that IGC Pharma has higher upside potential than Vaxcyte, analysts believe IGC Pharma is more attractive than Vaxcyte.

    Company Buy Ratings Hold Ratings Sell Ratings
    PCVX
    Vaxcyte
    8 0 0
    IGC
    IGC Pharma
    2 0 0
  • Is PCVX or IGC More Risky?

    Vaxcyte has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGC Pharma has a beta of 1.325, suggesting its more volatile than the S&P 500 by 32.462%.

  • Which is a Better Dividend Stock PCVX or IGC?

    Vaxcyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vaxcyte pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PCVX or IGC?

    Vaxcyte quarterly revenues are --, which are smaller than IGC Pharma quarterly revenues of $412K. Vaxcyte's net income of -$103.1M is lower than IGC Pharma's net income of -$1.7M. Notably, Vaxcyte's price-to-earnings ratio is -- while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxcyte is -- versus 19.48x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PCVX
    Vaxcyte
    -- -- -- -$103.1M
    IGC
    IGC Pharma
    19.48x -- $412K -$1.7M
  • Which has Higher Returns PCVX or NBY?

    NovaBay Pharmaceuticals has a net margin of -- compared to Vaxcyte's net margin of -49.65%. Vaxcyte's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    PCVX
    Vaxcyte
    -- -$0.83 --
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About PCVX or NBY?

    Vaxcyte has a consensus price target of $149.89, signalling upside risk potential of 67.87%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 447.79%. Given that NovaBay Pharmaceuticals has higher upside potential than Vaxcyte, analysts believe NovaBay Pharmaceuticals is more attractive than Vaxcyte.

    Company Buy Ratings Hold Ratings Sell Ratings
    PCVX
    Vaxcyte
    8 0 0
    NBY
    NovaBay Pharmaceuticals
    2 0 0
  • Is PCVX or NBY More Risky?

    Vaxcyte has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

  • Which is a Better Dividend Stock PCVX or NBY?

    Vaxcyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vaxcyte pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PCVX or NBY?

    Vaxcyte quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Vaxcyte's net income of -$103.1M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Vaxcyte's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxcyte is -- versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PCVX
    Vaxcyte
    -- -- -- -$103.1M
    NBY
    NovaBay Pharmaceuticals
    0.07x -- $2.4M -$1.2M
  • Which has Higher Returns PCVX or PFE?

    Pfizer has a net margin of -- compared to Vaxcyte's net margin of 25.23%. Vaxcyte's return on equity of -- beat Pfizer's return on equity of 4.63%.

    Company Gross Margin Earnings Per Share Invested Capital
    PCVX
    Vaxcyte
    -- -$0.83 --
    PFE
    Pfizer
    70.27% $0.78 $159.2B
  • What do Analysts Say About PCVX or PFE?

    Vaxcyte has a consensus price target of $149.89, signalling upside risk potential of 67.87%. On the other hand Pfizer has an analysts' consensus of $31.18 which suggests that it could grow by 18.9%. Given that Vaxcyte has higher upside potential than Pfizer, analysts believe Vaxcyte is more attractive than Pfizer.

    Company Buy Ratings Hold Ratings Sell Ratings
    PCVX
    Vaxcyte
    8 0 0
    PFE
    Pfizer
    7 13 1
  • Is PCVX or PFE More Risky?

    Vaxcyte has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer has a beta of 0.644, suggesting its less volatile than the S&P 500 by 35.588%.

  • Which is a Better Dividend Stock PCVX or PFE?

    Vaxcyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.41% to investors and pays a quarterly dividend of $0.42 per share. Vaxcyte pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

  • Which has Better Financial Ratios PCVX or PFE?

    Vaxcyte quarterly revenues are --, which are smaller than Pfizer quarterly revenues of $17.7B. Vaxcyte's net income of -$103.1M is lower than Pfizer's net income of $4.5B. Notably, Vaxcyte's price-to-earnings ratio is -- while Pfizer's PE ratio is 35.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxcyte is -- versus 2.51x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PCVX
    Vaxcyte
    -- -- -- -$103.1M
    PFE
    Pfizer
    2.51x 35.43x $17.7B $4.5B

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Does Cem Karsan Think the Market Is Headed in 2025?
Where Does Cem Karsan Think the Market Is Headed in 2025?

Cem Karsan, the founder and managing partner of Kai Volatility…

How To Create A Covered Call Trade Strategy
How To Create A Covered Call Trade Strategy

After you have done some homework on a stock and…

How To Use Covered Calls To Generate Income
How To Use Covered Calls To Generate Income

The Covered Call Defined A covered call is the sale…

Stock Ideas

Sell
49
Is AAPL Stock a Buy?

Market Cap: $3.6T
P/E Ratio: 39x

Sell
47
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 114x

Sell
46
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 36x

Alerts

Sell
43
QMCO alert for Jan 16

Quantum [QMCO] is up 15.13% over the past day.

Sell
34
IONQ alert for Jan 16

IonQ [IONQ] is up 4.98% over the past day.

Sell
47
FTAI alert for Jan 16

FTAI Aviation [FTAI] is up 3.34% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock